Compare Stocks: GDTC, APLM, DYAI, and LTRN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$18.12 -0.2%	$17.75	$3.66 ▼ $42.12	$39.26M	1.46	16,268 shs	177 shs
DYAI Dyadic International	$1.01 -3.9%	$0.96	$0.65 ▼ $1.60	$36.88M	1.12	178,708 shs	6,117 shs
GDTC CytoMed Therapeutics	$0.82 -2.5%	$1.00	$0.68 ▼ $3.68	$9.74M	0.04	269,233 shs	1,834 shs
LTRN Lantern Pharma	$2.75 -1.0%	$3.37	$1.11 ▼ $4.86	$35.55M	2.35	334,890 shs	6,354 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	+1.74%	+5.09%	-4.17%	+30.88%	+215.61%
DYAI Dyadic International	+5.51%	-2.78%	-0.94%	+47.78%	+29.65%
GDTC CytoMed Therapeutics	+5.11%	-1.30%	-18.35%	+11.39%	-53.28%
LTRN Lantern Pharma	-1.07%	+1.09%	-22.78%	+10.76%	-35.80%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$18.12 -0.2%	$17.75	$3.66 ▼ $42.12	$39.26M	1.46	16,268 shs	177 shs
DYAI Dyadic International	$1.01 -3.9%	$0.96	$0.65 ▼ $1.60	$36.88M	1.12	178,708 shs	6,117 shs
GDTC CytoMed Therapeutics	$0.82 -2.5%	$1.00	$0.68 ▼ $3.68	$9.74M	0.04	269,233 shs	1,834 shs
LTRN Lantern Pharma	$2.75 -1.0%	$3.37	$1.11 ▼ $4.86	$35.55M	2.35	334,890 shs	6,354 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	+1.74%	+5.09%	-4.17%	+30.88%	+215.61%
DYAI Dyadic International	+5.51%	-2.78%	-0.94%	+47.78%	+29.65%
GDTC CytoMed Therapeutics	+5.11%	-1.30%	-18.35%	+11.39%	-53.28%
LTRN Lantern Pharma	-1.07%	+1.09%	-22.78%	+10.76%	-35.80%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLM Apollomics	1.00	Sell	N/A	N/A
DYAI Dyadic International	2.33	Hold	$3.00	197.32% Upside
GDTC CytoMed Therapeutics	1.00	Sell	N/A	N/A
LTRN Lantern Pharma	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest GDTC, APLM, DYAI, and LTRN Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/29/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/14/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/13/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	GDTC CytoMed Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/29/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	DYAI Dyadic International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/23/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/4/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/22/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/14/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLM Apollomics	$8.50M	4.69	N/A	N/A	($2.89) per share	-6.27
DYAI Dyadic International	$3.09M	11.90	N/A	N/A	$0.03 per share	33.63
GDTC CytoMed Therapeutics	$324.39K	29.98	N/A	N/A	$0.45 per share	1.83
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$0.58 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLM Apollomics	-$10.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/24/2026 (Estimated)
DYAI Dyadic International	-$7.36M	-$0.23	N/A	N/A	N/A	-192.40%	-1,005.45%	-77.64%	8/12/2026 (Estimated)
GDTC CytoMed Therapeutics	-$3.10M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	-$17.12M	-$1.45	N/A	N/A	N/A	N/A	-198.34%	-129.08%	8/14/2026 (Confirmed)

Latest GDTC, APLM, DYAI, and LTRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	DYAI Dyadic International	-$0.0350	-$0.06	-$0.0250	-$0.06	$1.03 million	$0.96 million
8/12/2026	Q2 2026	LTRN Lantern Pharma	-$0.38	N/A	N/A	N/A	N/A	N/A
5/15/2026	Q1 2026	LTRN Lantern Pharma	-$0.36	-$0.30	+$0.06	-$0.30	N/A	N/A
5/13/2026	Q1 2026	DYAI Dyadic International	-$0.04	-$0.05	-$0.01	-$0.05	$0.90 million	$1.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLM Apollomics	N/A	N/A	N/A	N/A	N/A
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
GDTC CytoMed Therapeutics	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLM Apollomics	N/A	0.96	0.96
DYAI Dyadic International	4.08	2.42	2.42
GDTC CytoMed Therapeutics	0.06	5.17	5.17
LTRN Lantern Pharma	N/A	1.87	1.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLM Apollomics	19.13%
DYAI Dyadic International	27.95%
GDTC CytoMed Therapeutics	0.04%
LTRN Lantern Pharma	28.62%

Insider Ownership

Company	Insider Ownership
APLM Apollomics	N/A
DYAI Dyadic International	20.90%
GDTC CytoMed Therapeutics	N/A
LTRN Lantern Pharma	8.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLM Apollomics	45	2.20 million	N/A	Not Optionable
DYAI Dyadic International	7	36.44 million	28.82 million	Optionable
GDTC CytoMed Therapeutics	N/A	11.83 million	N/A	Not Optionable
LTRN Lantern Pharma	20	12.76 million	11.67 million	Optionable

GDTC, APLM, DYAI, and LTRN Headlines

Recent News About These Companies

Lantern Pharma (LTRN) Expected to Release Earnings on Wednesday

August 11 at 2:42 AM | americanbankingnews.com

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of ...

August 4, 2026 | finance.yahoo.com

Lantern Pharma Spins Off Open-Medicine AI Platform

August 3, 2026 | tipranks.com

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

August 3, 2026 | businesswire.com

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

July 28, 2026 | businesswire.com

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

July 23, 2026 | businesswire.com

Why Lantern Pharma Inc.’s (LTRN) Stock Is Down 5.14%

July 8, 2026 | aaii.comA

Lantern Pharma Launches ZetaOmics™ - an Autonomous, Intelligent "Computational Biologist" That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer

July 8, 2026 | tmcnet.com

Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer

July 8, 2026 | businesswire.com

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

June 2, 2026 | businesswire.com

Lantern Pharma Highlights Harmonic LP-300 Phase 2 Progress

June 2, 2026 | tipranks.com

Lantern Pharma (LTRN) Q1 2025 Earnings Transcript

May 21, 2026 | finance.yahoo.com

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

May 19, 2026 | businesswire.com

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

May 15, 2026 | businesswire.com

Insider Buying: Lantern Pharma (NASDAQ:LTRN) Director Acquires 48,544 Shares of Stock

May 15, 2026 | insidertrades.com

Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

May 14, 2026 | finance.yahoo.com

Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

May 13, 2026 | businesswire.com

Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

May 11, 2026 | businesswire.com

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript

April 30, 2026 | seekingalpha.com

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery Transcript

April 30, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GDTC, APLM, DYAI, and LTRN Company Descriptions

Apollomics NASDAQ:APLM

$18.12 -0.04 (-0.20%)

As of 10:04 AM Eastern

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Dyadic International NASDAQ:DYAI

$1.01 -0.04 (-3.90%)

As of 10:02 AM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

CytoMed Therapeutics NASDAQ:GDTC

$0.82 -0.02 (-2.47%)

As of 10:03 AM Eastern

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

Lantern Pharma NASDAQ:LTRN

$2.75 -0.03 (-1.04%)

As of 10:04 AM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GDTC, APLM, DYAI, and LTRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GDTC, APLM, DYAI, and LTRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GDTC, APLM, DYAI, and LTRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GDTC, APLM, DYAI, and LTRN Company Descriptions

Apollomics NASDAQ:APLM

Dyadic International NASDAQ:DYAI

CytoMed Therapeutics NASDAQ:GDTC

Lantern Pharma NASDAQ:LTRN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GDTC, APLM, DYAI, and LTRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GDTC, APLM, DYAI, and LTRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GDTC, APLM, DYAI, and LTRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GDTC, APLM, DYAI, and LTRN Company Descriptions

Apollomics NASDAQ:APLM

Dyadic International NASDAQ:DYAI

CytoMed Therapeutics NASDAQ:GDTC

Lantern Pharma NASDAQ:LTRN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools